STOCK TITAN

Vivani Medical (VANI) Financials

VANI NASDAQ
FY2025 annual
Revenue $0 n/m YoY
Net Income -$26.6M n/m YoY
EPS (Diluted) -$0.43 n/m YoY
Free Cash Flow -$25.5M n/m YoY
Market Cap $102.8M as of Nov 20, 2026
Price / Sales n/m revenue is not positive, FY2025
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 7.8x on $13.2M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VANI SEC filings page.

Vivani Medical, Inc. (VANI) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VANI FY2025

Vivani remains development-stage, with expanding research spending, recurring cash losses, and a balance sheet increasingly funded by liabilities.

The company’s development-led cost structure is visible in FY2025: research and development consumed $18.1M while the operating loss reached $27.6M. Operating cash flow of -$24.3M broadly tracked the net loss of $26.6M, indicating that reported losses are translating into cash needs rather than being mainly accounting charges.

The balance sheet has become more liability-dependent: liabilities were 60.1% of assets in FY2025 versus 54.7% in FY2023. Equity declined 10.7% in FY2025, while a 2.7x current ratio still indicates current assets exceeded current liabilities; the supplied liquidity comparison equaled 8 months of the latest annual operating outflow.

Cash requirements remain substantial: operating cash flow was -$24.3M and free cash flow was -$25.5M. Capital expenditures rose 111.0% to $1.2M, yet total assets fell 5.2%, so added investment has not translated into a larger reported asset base.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Vivani Medical, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Distress
-4.64

Vivani Medical, Inc. scores -4.64, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $148.5M against total assets of $39.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
1/7

Vivani Medical, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Vivani Medical, Inc. reported a net loss of $26.6M while operations used $24.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$7.4M
YoYn/m
QoQn/m
5Y CAGRn/m

Vivani Medical, Inc.'s EBITDA was -$7.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$7.3M
YoYn/m
QoQn/m
5Y CAGRn/m

Vivani Medical, Inc. reported a net loss of $7.3M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.08
YoYn/m
QoQn/m

Vivani Medical, Inc. earned -$0.08 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$6.4M
YoYn/m
QoQn/m

Vivani Medical, Inc. recorded an outflow of $6.4M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$14.6M
YoY+455.2%
QoQ-26.7%
5Y CAGR+65.5%

Vivani Medical, Inc. held $14.6M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
90M
YoY+23.6%
QoQ0.0%
5Y CAGR+18.0%

Vivani Medical, Inc. had 90M shares outstanding in Q3 2026. This represents an increase of 23.6% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-54.9%
YoY+444.0pp
QoQ-21.3pp

Vivani Medical, Inc.'s quarterly ROE was -54.9% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 444.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 21.3 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$5.0M
YoY+11.1%
QoQ+12.7%

Vivani Medical, Inc. invested $5.0M in research and development in Q3 2026. This represents an increase of 11.1% from the same quarter a year earlier. Against the prior quarter it is up 12.7%.

Capital Expenditures
$0
YoY-100.0%
QoQ-100.0%

Vivani Medical, Inc. reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

VANI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VANI quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
RevenueN/AN/AN/AN/AN/AN/A$0N/A
R&D Expenses$5.0M+11.1%$4.5M-6.4%$4.4M+4.1%$4.6M+7.6%$4.5M+7.5%$4.8M+35.5%$4.2M+13.2%$4.3M-8.6%
SG&A Expenses$2.5M+13.8%$2.4M-10.5%$2.4M+3.7%$2.2M+1.1%$2.2M+4.7%$2.7M+24.7%$2.3M-6.4%$2.2M+42.9%
Operating Income-$7.5Mn/m-$6.9Mn/m-$6.8Mn/m-$6.8Mn/m-$6.7Mn/m-$7.5Mn/m-$6.6Mn/m-$6.5Mn/m
EBITDA-$7.4Mn/m-$6.7Mn/m-$6.7Mn/m-$6.7Mn/m-$6.6Mn/m-$7.4Mn/m-$6.5Mn/m-$6.4Mn/m
Net Income-$7.3Mn/m-$6.4Mn/m-$6.8Mn/m-$6.6Mn/m-$6.5Mn/m-$7.1Mn/m-$6.3Mn/m-$6.0Mn/m
EPS (Basic)-$0.08n/m-$0.07n/m-$0.08n/m-$0.09n/m-$0.11n/m-$0.12n/m-$0.11n/m-$0.11
EPS (Diluted)-$0.08n/m-$0.07n/m-$0.08n/m-$0.09n/m-$0.11n/m-$0.12n/m-$0.11n/m-$0.11
Diluted Shares (Avg)90M+50.9%87M+47.0%81M+37.2%N/A60M+8.1%59M+7.7%59M+13.5%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

VANI Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VANI quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$35.3M+41.0%$41.6M+44.1%$42.4M+19.5%$39.4M-5.2%$25.0M-41.6%$28.9M-40.1%$35.5M-34.1%$41.6M-9.2%
Current Assets$15.8M+279.2%$21.6M+148.3%$21.5M+45.1%$17.9M-12.4%$4.2M-80.5%$8.7M-66.9%$14.8M-52.9%$20.4M-11.4%
Cash & Equivalents$14.6M+455.2%$19.9M+192.8%$19.7M+51.8%$16.2M-11.6%$2.6M-86.6%$6.8M-72.7%$13.0M-56.1%$18.4M-11.1%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$22.1M-6.9%$22.7M-5.5%$23.3M-2.4%$23.7M-1.2%$23.7M-3.4%$24.0M-1.7%$23.8M-5.0%$24.0M-4.3%
Current Liabilities$6.6M-3.6%$6.7M-0.8%$6.8M+9.3%$6.6M+10.3%$6.8M+8.9%$6.7M+16.1%$6.2M+1.0%$6.0M+4.6%
Non-Current Liabilities$15.5M-8.3%$16.0M-7.3%$16.5M-6.4%$17.1M-5.0%$16.9M-7.6%$17.3M-7.2%$17.6M-6.9%$18.0M-7.0%
Total Equity$13.2M+909.8%$19.0M+286.3%$19.1M+64.2%$15.7M-10.7%$1.3M-92.9%$4.9M-79.4%$11.6M-59.5%$17.6M-15.2%
Retained Earnings-$168.9Mn/m-$161.7Mn/m-$155.3Mn/m-$148.5Mn/m-$141.9Mn/m-$135.4Mn/m-$128.2Mn/m-$121.9Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

VANI Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VANI quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$6.4Mn/m-$6.0Mn/m-$6.2Mn/m-$6.7Mn/m-$6.4Mn/m-$6.1Mn/m-$5.2Mn/m-$5.8Mn/m
Depreciation & Amortization$129K+22.9%$128K+25.5%$130K+27.5%$115K+29.2%$105K-6.3%$102K+2.0%$102K+3.0%$89K-9.2%
Stock-Based Compensation$378K+37.0%$313K-19.9%$312K-10.9%N/A$276K-41.5%$391K+2.1%$350K-0.8%N/A
Capital Expenditures$0-100.0%$99K+39.4%$3K-40.0%$274K-7.4%$823K+1907.3%$71K+91.9%$5K-97.3%$296K-60.2%
Free Cash Flow-$6.4Mn/m-$6.1Mn/m-$6.2Mn/m-$7.0Mn/m-$7.2Mn/m-$6.2Mn/m-$5.2Mn/m-$6.1Mn/m
Investing Cash Flow$0n/m-$99Kn/m-$3Kn/m-$274Kn/m-$823Kn/m-$71Kn/m-$5Kn/m-$296Kn/m
Financing Cash Flow$1.1M-63.1%$5.8Mn/m$9.7Mn/m$20.6M+326.5%$2.9M+590.4%-$95K-187.2%-$170K-101.2%$4.8M+20891.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

VANI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VANI quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-54.9%+444.0pp-33.6%+111.9pp-35.5%+18.7pp-42.2%-7.8pp-498.9%-465.9pp-145.5%-123.0pp-54.2%-33.2pp-34.4%-5.3pp
Return on Assets-20.5%+5.5pp-15.3%+9.4pp-16.0%+1.8pp-16.8%-2.3pp-26.1%-12.0pp-24.7%-13.6pp-17.8%-6.6pp-14.6%-1.4pp
Current Ratio2.40+1.8x3.25+2.0x3.18+0.8x2.71-0.7x0.61-2.8x1.30-3.3x2.40-2.7x3.42-0.6x
Liabilities-to-Equity1.67-16.5x1.20-3.7x1.22-0.8x1.50+0.1x18.13+16.8x4.89+3.9x2.05+1.2x1.36+0.2x
Asset TurnoverN/AN/AN/AN/AN/AN/A0.00N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Vivani Medical, Inc. VANI FY2025 $0 -$26.6M N/A $102.8M —
Minerva Neurosciences, Inc NERV FY2025 N/A -$293.4M N/A $99.7M —
Armata Pharmaceuticals, Inc. ARMP FY2025 N/A -$173.8M N/A $112.7M —
OnKure Therapeutics, Inc. OKUR FY2025 N/A -$59.5M N/A $111.2M —
Jyong Biotech Ltd. MENS FY2025 N/A -$4.7M N/A $107.6M —
Genelux Corporation GNLX FY2025 $8K -$32.1M N/A $103.4M —

Frequently Asked Questions

Vivani Medical, Inc. (VANI) reported $0 in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Vivani Medical, Inc. (VANI) reported a net loss of $26.6M in fiscal year 2025.

Vivani Medical, Inc. (VANI) reported diluted earnings per share of -$0.43 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vivani Medical, Inc. (VANI) had EBITDA of -$27.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Vivani Medical, Inc. (VANI) has a return on equity of -169.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Vivani Medical, Inc. (VANI) recorded an outflow of $25.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Vivani Medical, Inc. (VANI) recorded an outflow of $24.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Vivani Medical, Inc. (VANI) had $39.4M in total assets as of fiscal year 2025, including both current and long-term assets.

Vivani Medical, Inc. (VANI) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Vivani Medical, Inc. (VANI) invested $18.1M in research and development during fiscal year 2025.

Vivani Medical, Inc. (VANI) had 85M shares outstanding as of fiscal year 2025.

Vivani Medical, Inc. (VANI) had a current ratio of 2.71 as of fiscal year 2025, which is generally considered healthy.

Vivani Medical, Inc. (VANI) had a liabilities-to-equity ratio of 1.50 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Vivani Medical, Inc. (VANI) had a return on assets of -67.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Vivani Medical, Inc. (VANI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $102.8M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Vivani Medical, Inc. (VANI) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $102.8M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Vivani Medical, Inc. (VANI) held $16.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $24.3M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Vivani Medical, Inc. (VANI) has an Altman Z-Score of -4.64, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Vivani Medical, Inc. (VANI) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Vivani Medical, Inc. (VANI) reported a net loss of $26.6M while operations used $24.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top